- Active not recruitingPHASE3
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
This study is looking at a new combination of medicines, capivasertib and fulvestrant, for women and men with a specific type of advanced breast cancer. It compares this combination to fulvestrant plus a dummy drug to see if it works better.
For: Locally Advanced (Inoperable) or Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
This study looks at a new drug, capivasertib, combined with standard treatment (abiraterone and ADT) for men with prostate cancer that has spread and is sensitive to hormone treatment. It's for men whose cancer has a specific change called PTEN deficiency.
For: Hormone-Sensitive Prostate CancerUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study looks at new drug combinations for metastatic triple-negative breast cancer. It combines standard treatment with new medicines (like Durvalumab) to see if they're safe and work well together for patients whose cancer has spread.
For: Triple Negative Breast NeoplasmsUnited States · Canada · Poland - Active not recruitingPHASE3
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
This study compares two treatments for advanced prostate cancer that has spread and no longer responds to hormone therapy. It tests if adding a new drug, capivasertib, to standard chemotherapy (docetaxel) works better than chemotherapy alone to help patients live longer and keep the cancer from growing.
For: Prostate CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
This study is looking into a new combination treatment for a type of breast cancer called triple-negative breast cancer (TNBC) that has spread or is advanced. It combines a new drug, Capivasertib, with a common chemotherapy, Paclitaxel, to see if it works better than just Paclitaxel alone.
For: Triple Negative Breast NeoplasmsUnited States · Argentina · Brazil - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - Active not recruitingPHASE3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
This study looks at a new combination treatment for advanced breast cancer that's hormone-positive and HER2-negative. It combines a new drug called capivasertib with existing treatments to see if it works better at slowing down the cancer's growth.
For: Locally Advanced (Inoperable) or Metastatic Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
This study compares two drug combinations, RLY-2608 with fulvestrant, and capivasertib with fulvestrant, for advanced breast cancer that has a specific gene change (PIK3CA mutation) and has grown after previous treatment. It's for HR+/HER2- breast cancer.
For: PIK3CA Mutation · HER2- Negative Breast Cancer · Hormone Receptor Positive TumorUnited States · Argentina · Australia - Active not recruitingPHASE2
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This study is testing different combinations of new drugs (olaparib, durvalumab, capivasertib, and cediranib) for recurrent or hard-to-treat womb cancer. The aim is to find out if these combinations can stop the cancer from growing or spreading more effectively.
For: Endometrial Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous AdenocarcinomaUnited States · Canada - RecruitingPHASE3
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
This study is testing a new drug, capivasertib, for advanced breast cancer that's grown despite previous treatment. It aims to see how well it works and if it improves quality of life for patients.
For: Breast Cancer · HR-positive Breast Cancer · Advanced Breast CancerBelgium · Germany · Portugal - Active not recruitingPHASE1, PHASE2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
This study is testing a new drug called elacestrant with other breast cancer medicines. It's for people with a specific type of advanced breast cancer that has spread. The main goals are to see if these drug combinations are safe and if they can help shrink the cancer.
For: Breast Cancer · Metastatic Breast CancerUnited States · Argentina · Australia